ACHN News Alert Achillion Pharmaceuticals (ACHN) 13.33 01/03/2015

New Post Public Reply Private Reply Replies (0) Message Board

Jan 3, 2015 at 2:18 PM

Achillion Pharmaceuticals (ACHN) 13.33 $ACHN

The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 91.26 (-0.46), TTPH: 39.72 (+0.01), AVNR: 16.94 (-0.01), SWKS: 73.32 (+0.61), CMRX: 41.78 (+1.52), ACHN: 13.33 (+1.08), HA: 25.27 (-0.78), RCPT: 124.81 (+2.30), PTCT: 51.00 (-0.77), AGIO: 109.76 (-2.28)

One Reason Achillion Pharmaceuticals (ACHN) Stock is Rising Today
at The Street - Fri Jan 02, 11:18AM CST
Shares of Achillion Pharmaceuticals (ACHN) were up Friday after Roth Capital analyst Peter Kolchinsky identified the company as an attractive takeover target.
ACHN: 13.33 (+1.08)

Biotech Stocks 2014: The Best, Worst and Fastest-Growing
at The Street - Fri Jan 02, 7:33AM CST
Once again, biotech stocks greatly outperformed the broader market in 2014.
BLUE: 91.26 (-0.46), OVAS: 45.83 (+1.61), ACHN: 13.33 (+1.08), RCPT: 124.81 (+2.30), AGIO: 109.76 (-2.28)

3 Biotech Stocks That Soared Past Gilead in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Dec 30, 9:41AM CST
Gilead (GILD) has been under pressure due to the pricing of its hepatitis C virus (HCV) treatments.
JNJ: 104.52 (-0.05), ESRX: 84.65 (-0.02), VRTX: 123.07 (+4.27), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), ABBV: 65.89 (+0.45)

DoctoRx Positions For 2015: I Have Cut Back On My Exposure To All Biotech Substantially
SA Editors - Seeking Alpha - Tue Dec 30, 6:05AM CST
Today we present the fifth piece in Seeking Alpha's Positioning for 2015 series. This year we have once again asked experts on a range of different asset classes and investing strategies to offer their vision for the coming year and beyond....
BIIB: 342.01 (+2.56), SPY: 205.43 (-0.11), PTLA: 28.51 (+0.19), PCYC: 124.46 (+2.20), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), MRK: 57.19 (+0.40), EW: 127.72 (+0.34), IBB: 306.34 (+2.99), HQH: 31.87 (+0.38), REGN: 410.16 (-0.09), CELG: 113.52 (+1.66)

Could These Tiny Biotech Stocks Double in 2015?
Todd Campbell, The Motley Fool - Motley Fool - Tue Dec 30, 5:50AM CST
Biotechnology's mind-numbing share price volatility means that only the most risk-tolerant investors should consider owning them -- but for investors with a penchant for risk and a stomach tough enough to handle the inevitable pops and drops, there...
PTLA: 28.51 (+0.19), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), PFE: 31.33 (+0.18), OPHT: 45.60 (+0.73), BMY: 59.51 (+0.48), REGN: 410.16 (-0.09), NVS: 92.25 (-0.41)

The Zacks Analyst Blog Highlights: Tekmira, Chimerix, Gilead, AbbVie, Achillion Pharmaceuticals, Agios Pharmaceuticals, PTC Therapeutics and Tetraphase Pharmaceuticals
PR Newswire - Mon Dec 29, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Tekmira (Nasdaq:TKMR-Free Report), Chimerix (Nasdaq:CMRX-Free Report), Gilead (Nasdaq:GILD-Free Report), AbbVie (NYSE:ABBV-Free Report), Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Agios Pharmaceuticals, Inc. (Nasdaq:AGIO-Free Report), PTC Therapeutics, Inc. (Nasdaq

TCT-Free Report) and Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH-Free Report).
ACHN: 13.33 (+1.08), PTCT: 51.00 (-0.77), AGIO: 109.76 (-2.28)

Should AbbVie Inc. and Gilead Sciences, Inc. Fear This Biotech Instead of Each Other?
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 28, 10:11AM CST
Source: Gilead Sciences via Google Maps. Gilead Sciences shares tumbled following the approval of AbbVie 's new hepatitis C drug Viekira Pak, but both companies may find that their longer-term battle isn't with each other, but with Achillion...
ESRX: 84.65 (-0.02), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), ABBV: 65.89 (+0.45)

Seeking Alpha's Biotech Weekly: AbbVie Slaps Gilead, Achillion's 'Nuc' Power, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Dec 26, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
MGNX: 35.18 (+0.11), CYTK: 7.37 (-0.64), JNJ: 104.52 (-0.05), ESRX: 84.65 (-0.02), ALNY: 97.77 (+0.77), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), ABBV: 65.89 (+0.45), BMY: 59.51 (+0.48), ANIK: 39.76 (-0.98)

Most active Nasdaq-traded stocks
AP - Fri Dec 26, 12:21PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
ATOS: 1.40 (-0.03), GILD: 94.91 (+0.65), FB: 78.45 (+0.43), ACHN: 13.33 (+1.08), ARCP: 9.27 (+0.22), INTC: 36.36 (+0.07), GRPN: 8.02 (-0.24), AAPL: 109.33 (-1.05)

Nasdaq stocks posting largest percentage increases
AP - Wed Dec 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
KNDI: 13.04 (-0.97), WATT: 11.38 (+0.42), ACHN: 13.33 (+1.08), PLMT: 17.02 (+0.32)

February 2015 Options Now Available For Achillion Pharmaceuticals
at The Street - Wed Dec 24, 11:30AM CST
Investors in Achillion Pharmaceuticals Inc. saw new options begin trading today, for the February 2015 expiration.
ACHN: 13.33 (+1.08)

Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen Plunges on Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 24, 8:48AM CST
Will Express Scripts' announcement regarding AbbVie's (ABBV) Viekira Pak lead to a pricing war in the hepatitis C virus (HCV) market?
BIIB: 342.01 (+2.56), VRTX: 123.07 (+4.27), CBST: 100.76 (+0.11), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), IMGN: 6.49 (+0.39), ABBV: 65.89 (+0.45)

Premarket Gainers / Losers as of 9:10 ET
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 8:12AM CST

NVGS: 20.19 (-0.87), ACHN: 13.33 (+1.08), ADMS: 17.49 (+0.12), DGLY: 15.46 (+0.14)

The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 24, 8:03AM CST
For shareholders of Gilead Sciences it's practically been a dream year . Shares rose close to 40%, tacking on roughly $45 billion in market value, following the successful approval and launch of oral hepatitis C drugs Sovaldi and Harvoni. ...
JNJ: 104.52 (-0.05), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), ABBV: 65.89 (+0.45), BMY: 59.51 (+0.48), ENTA: 50.45 (-0.40)

Achillion set for gap up at the open
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 8:01AM CST

ACHN: 13.33 (+1.08)

Achillion Gains on Positive Results from its HCV Candidates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:00PM CST
Achillion Pharmaceuticals (ACHN) gained more than 9% after announcing encouraging results from its HCV candidates.
JNJ: 104.52 (-0.05), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), AMGN: 159.89 (+0.60)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wendy's Faces Takeover Bid Amid Strategic Focus Shift

Behind the Unsolicited Offer Folks, it looks like Wendy's (NASDAQ:WEN) got itself mixed up in some high-stakes shenanigans. An unsolicited, non-binding proposal slammed into them, courtesy of the Investor Group led by Trian Partners, Flynn Group LP, BlueFive Capital, and Sixth Street Partners, itching to scoop up every last piece of Wendy’s stock they ain't already...

Beta Bionics: Investors on Edge, Legal Moves Underway

A Tumultuous Time for Beta Bionics Investors Trouble's brewing for those holding Beta Bionics, Inc. (NASDAQ: BBNX) shares. This isn't just market jitters—it's a full-blown legal tussle. The shareholder-rights law honchos at Johnson Fistel are sounding the alarms, and investors better heed their call before the clock strikes November 3, 2026. There's a class action...

Personalized Senior Living Guidance Finds Home in South Jersey

Shaunique Adams and Her Mission in South Jersey In a world where compassion sometimes feels like it's on short supply, Shaunique Adams is making sure it's at the forefront of her mission. Having experienced the emotional whirlwind of caregiving firsthand, Adams has transformed her personal journey into a mission to serve families navigating similar paths. Through Trua...

Northeast Indiana Bancorp Shows Solid Third Quarter Gains

Holding Steady in a Shaky Market In a market often rocked by turbulence, it seems Northeast Indiana Bancorp, Inc. has found a decent footing to stand on. Announcing their third-quarter results for 2026, they’ve posted net income of $1.991 million, showcasing a neat jump from the $1.793 million in the same period last year. Not bad at all for the parent company of First...

Air Canada-CAE Scholarship Drives Women in Aviation

A New Chapter for Women in Aviation Call it paving the skies or busting the glass cockpit ceiling, but Air Canada and CAE are really doubling down on getting more women into aviation. They're rolling out the eighth annual Captain Judy Cameron Scholarship, set to open applications on November 1, 2026. With up to eight scholarships on the table for Canadian women eyeing...

Beta Bionics Faces Securities Fraud Class Action Challenges

The Unexpected Slide of Beta Bionics So your wallet took a bruising with this Beta Bionics deal, eh? It’s another one of those wild tales from the stock jungle where everyone watching the NASDAQ:BBNX action got clipped when reality didn't match the company chest-thumping. Glancy Prongay Wolke & Rotter LLP just laid it out—ripping the Band-Aid off what Beta Bionics...

Fannie Mae Q3 2026 Earnings Surpass Expectations

An Upward Trend in Fannie Mae's Financials Hold onto your hats—Fannie Mae's swinging into action with hefty third-quarter numbers that'd make most firms drool. The latest figures, disclosed in their 10-Q filing, boast a net income of $4.2 billion for Q3 2026. You heard me right, billion! Now, to a market vet, these aren't digits to scoff at. And as the economy keeps...

Regal Healthcare: Five Years of Founder-Friendly Valor

Why Founder-Friendly Matters More Than Ever in Healthcare Well folks, in a year when everyone's tossing around terms like 'value-added' and 'strategic support', seeing Regal Healthcare Capital Partners snag slot number five straight on Inc.'s Founder-Friendly Investors list feels like catching a rare breed of fish twice. Seriously, these folks are stamping their forte as...

2021 Ferrari Portofino Shines Bright at Jake's Motorcars

San Diego might be known for its sunny weather, but Jake's Motorcars just cranked the heat with a 2021 Ferrari Portofino that flaunts a special-ordered Mandarin Orange interior. Now, if that doesn't scream "look at me," I don't know what does. For those who aren't just dabbling in Ferraris but are downright obsessed, let's dig into what makes this sports car not just...

Lilly's Retatrutide Outshines Ozempic in Key Diabetes Trial

Lilly's Breakthrough in Diabetes Treatment Eli Lilly's retatrutide is stirring up the diabetes treatment waters. The latest Phase 3 comparison to Ozempic's top dose reveals some surprising results. I'm not one to toss out kudos lightly, but this could be a genuine game-changer if things hold steady. A1C Reductions: A Close Look at the Numbers We’re staring down the...